Renal cell carcinoma is a rare and deadly form of cancer. New options bring relief in advanced cases where initial treatment has failed. Distributed by Tubemogul.
Read the full transcript »

Sherry Dematarco: We know cell carcinoma or the kidney cancer is on the rise with an rise with an estimated 4600 new cases reported in Canada in 2009. for those at an advance stage of the disease, patients had little hope once initial treatment options failed. But now an important breakthrough with Health Canada's approval of Afinitor . Dr. Sebastien Hotte, is a medical oncologist with the Juravinski Cancer Center, and contributing investigator of the RECORD-1 trial, the basis for Health Canada's approval of Afinitor. Dr. Sebastien Hotte: The clinical trial that compared Afinitor or Everolimus to placebo, showed a number of things. Firstly, the 25% of patients who were on Afinitor were free of progression at 10 months into their treatment as well the improvement in the time that it takes for patients to get worse was two thirds. Sherry Dematarco: In cancer cells, Afinitor continuously targets mTOR, a protein that acts as a central regulator of tumor cell division, blood vessel growth and cell metabolism. Dr. Sebastien Hotte: Unfortunately, 40% of patients are diagnosed with advance disease at the time of their diagnosis and significant amount of patients develop advance disease later on, Everolimus or Afinitor should be considered after first line treatments for these patients and this has been shown in the most recent clinical trial. Sherry Dematarco: Deborah Maskens is the vice-chairman of Kidney Cancer Canada. Deborah Maskens: There has been some tremendous developments in the treatment of kidney cancer in the last five years and these new target achievements are really helping us manage our disease that's been traditionally very hard to treat. For patients with advance kidney cancer, Afinitor brings them tremendous hope that they will have access to a treatment option after their first line of therapy fails. What patients really need right now is access to therapies in sequential order so that they can continue to maintain a good quality of life. Sherry Dematarco: for more information about driven options for kidney cancers, speak with your doctor. To learn about more kidney cancer, please visit kidneycancercanada.ca. Sherry Dematarco reporting.

Advertisement
Advertisement
Advertisement